I study disease progression and treatment resistance in prostate, bladder and testicular cancer. I am interested in how tumors evolve in response to therapy; I find their adaptability fascinating. Conventionally, patient tissue biopsies are necessary for this type of research. However, my research utilizes minimally-invasive blood draws, often referred to as liquid biopsies. From these standard blood draws, I profile the circulating tumour DNA present in patients’ bloodstreams. This technology provides real-time genetic information that enables clinicians to deliver a more personalized treatment plan to their patients.
